An alternate binding site for PPARγ ligands

PPARγ is a target for insulin-sensitizing drugs such as glitazones, which improve plasma glucose maintenance in patients with diabetes. Synthetic ligands have been designed to mimic endogenous ligand binding to a canonical ligand-binding pocket to hyperactivate PPARγ. Here we reveal that synthetic P...

Full description

Saved in:
Bibliographic Details
Published in:Nature communications 2014-04, Vol.5 (1), p.3571-3571, Article 3571
Main Authors: Hughes, Travis S, Giri, Pankaj Kumar, de Vera, Ian Mitchelle S, Marciano, David P, Kuruvilla, Dana S, Shin, Youseung, Blayo, Anne-Laure, Kamenecka, Theodore M, Burris, Thomas P, Griffin, Patrick R, Kojetin, Douglas J
Format: Article
Language:English
Subjects:
Binding Sites
Ligands
PPAR gamma - chemistry
PPAR gamma - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:PPARγ is a target for insulin-sensitizing drugs such as glitazones, which improve plasma glucose maintenance in patients with diabetes. Synthetic ligands have been designed to mimic endogenous ligand binding to a canonical ligand-binding pocket to hyperactivate PPARγ. Here we reveal that synthetic PPARγ ligands also bind to an alternate site, leading to unique receptor conformational changes that impact coregulator binding, transactivation and target gene expression. Using structure-function studies we show that alternate site binding occurs at pharmacologically relevant ligand concentrations, and is neither blocked by covalently bound synthetic antagonists nor by endogenous ligands indicating non-overlapping binding with the canonical pocket. Alternate site binding likely contributes to PPARγ hyperactivation in vivo, perhaps explaining why PPARγ full and partial or weak agonists display similar adverse effects. These findings expand our understanding of PPARγ activation by ligands and suggest that allosteric modulators could be designed to fine tune PPARγ activity without competing with endogenous ligands.
ISSN:2041-1723
2041-1723
DOI:10.1038/ncomms4571